BERGEN, Norway, October 16, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that a poster and an oral
presentation summarizing completed studies with its lead product candidate
bemcentinib will be presented at the upcoming European Society of Clinical
Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron
University Hospital, Spain will present the following poster summarizing the
final results from the BGBC008 Phase II study of bemcentinib in combination with
pembrolizumab in 2L NSCLC:

Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study
of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non
-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
Session Date:  Onsite poster display date, Monday October 23
Poster Board Number: 1440P

The poster will be available on BerGenBio's website shortly following
presentation.

In addition, Dr. Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical
Science at the Haukeland University Hospital in Bergen, Norway will make an oral
presentation summarizing the results of the Investigator Led Study LBA52 with
bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L
metastatic melanoma patients:

Oral Presentation Title: A randomized Phase Ib/II study of the selective small
molecule AXL inhibitor bemcentinib in combination with either
dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

Session Name:  LBA 52 "Melanoma and other skin tumors"
Session Date and Time: Saturday October 21, 15:50-15:55 CET
Location: Leon Auditorium, Hall 7

Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to
share more data on bemcentinib which we believe substantiates our strategy to
focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of
potentiating the effects of standard of care treatments.  We thank the patients
who participated in these studies, their families, and all participating
investigators as well as their clinical and nursing staff for contributing to
our understanding of bemcentinib as a potential cancer therapeutic."

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com



Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.